Charles Schwab Investment Management Inc. Raises Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Charles Schwab Investment Management Inc. raised its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 146.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,110,460 shares of the biopharmaceutical company's stock after buying an additional 660,080 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.71% of Ocular Therapeutix worth $9,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of OCUL. Deltec Asset Management LLC grew its stake in shares of Ocular Therapeutix by 9.6% during the second quarter. Deltec Asset Management LLC now owns 2,590,265 shares of the biopharmaceutical company's stock valued at $17,717,000 after buying an additional 226,181 shares during the last quarter. Banco Santander S.A. grew its position in shares of Ocular Therapeutix by 81.3% during the 2nd quarter. Banco Santander S.A. now owns 377,368 shares of the biopharmaceutical company's stock worth $2,581,000 after buying an additional 169,172 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Ocular Therapeutix by 39.1% during the second quarter. Rhumbline Advisers now owns 211,301 shares of the biopharmaceutical company's stock valued at $1,445,000 after buying an additional 59,345 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Ocular Therapeutix by 49.6% in the second quarter. Bank of New York Mellon Corp now owns 495,635 shares of the biopharmaceutical company's stock valued at $3,390,000 after acquiring an additional 164,383 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Ocular Therapeutix in the third quarter worth about $393,000. 59.21% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the company's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $9.01, for a total value of $26,561.48. Following the completion of the transaction, the insider now owns 269,059 shares in the company, valued at approximately $2,424,221.59. This represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 3.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. Scotiabank began coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Ocular Therapeutix presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.71.

Ocular Therapeutix Stock Performance

NASDAQ:OCUL traded up $0.02 during midday trading on Tuesday, hitting $9.37. The company's stock had a trading volume of 340,160 shares, compared to its average volume of 1,797,864. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a fifty-two week low of $3.24 and a fifty-two week high of $11.77. The firm's 50 day moving average is $10.07 and its 200-day moving average is $8.42. The firm has a market cap of $1.47 billion, a P/E ratio of -7.08 and a beta of 1.20.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.